RU2006101149A - Рекомбинантный адено-ассоциированный вирусный вектор для лечения болезни альцгеймера - Google Patents
Рекомбинантный адено-ассоциированный вирусный вектор для лечения болезни альцгеймера Download PDFInfo
- Publication number
- RU2006101149A RU2006101149A RU2006101149/13A RU2006101149A RU2006101149A RU 2006101149 A RU2006101149 A RU 2006101149A RU 2006101149/13 A RU2006101149/13 A RU 2006101149/13A RU 2006101149 A RU2006101149 A RU 2006101149A RU 2006101149 A RU2006101149 A RU 2006101149A
- Authority
- RU
- Russia
- Prior art keywords
- viral vector
- adeno
- associated viral
- vector according
- specified
- Prior art date
Links
- 239000013603 viral vector Substances 0.000 title claims 14
- 208000024827 Alzheimer disease Diseases 0.000 title claims 4
- DZHSAHHDTRWUTF-SIQRNXPUSA-N amyloid-beta polypeptide 42 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(C)C)C1=CC=CC=C1 DZHSAHHDTRWUTF-SIQRNXPUSA-N 0.000 claims 10
- 108010076504 Protein Sorting Signals Proteins 0.000 claims 5
- 150000001413 amino acids Chemical class 0.000 claims 5
- 239000002773 nucleotide Substances 0.000 claims 5
- 125000003729 nucleotide group Chemical group 0.000 claims 5
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 101710137189 Amyloid-beta A4 protein Proteins 0.000 claims 1
- 101710151993 Amyloid-beta precursor protein Proteins 0.000 claims 1
- 102100022704 Amyloid-beta precursor protein Human genes 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 210000001723 extracellular space Anatomy 0.000 claims 1
- 230000000968 intestinal effect Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- 108010033276 Peptide Fragments Proteins 0.000 abstract 2
- 102000007079 Peptide Fragments Human genes 0.000 abstract 2
- 241000702421 Dependoparvovirus Species 0.000 abstract 1
- 230000004727 humoral immunity Effects 0.000 abstract 1
- 230000006698 induction Effects 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- C12N15/861—Adenoviral vectors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
- C12N2799/025—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a parvovirus
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Neurology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Toxicology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Wood Science & Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- General Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Neurosurgery (AREA)
- Plant Pathology (AREA)
- Psychiatry (AREA)
- Virology (AREA)
- Physics & Mathematics (AREA)
- Hospice & Palliative Care (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Claims (14)
1. Адено-ассоциированный вирусный вектор для экспрессии β-амилоидного пептида в клетках кишечника, включающий в себя ДНК, кодирующую указанный β-амилоидный пептид, и ДНК, кодирующую сигнальный пептид, позволяющий указанному β-амилоидному пептиду секретироваться во внеклеточное пространство, в оперативной форме.
2. Адено-ассоциированный вирусный вектор по п.1, где указанный β-амилоидный пептид включает в себя аминокислоты с 4-й по 10-ю в аминокислотной последовательности, приведенной в SEQ ID NO: 2.
3. Адено-ассоциированный вирусный вектор по п.1, где ДНК, кодирующая указанный β-амилоидный пептид, включает в себя нуклеотиды с 10-го по 30-й в нуклеотидной последовательности, приведенной в SEQ ID NO: 1.
4. Адено-ассоциированный вирусный вектор по п.1, где указанный β-амилоидный пептид включает в себя аминокислотную последовательность, приведенную в SEQ ID NO: 2.
5. Адено-ассоциированный вирусный вектор по п.1, где ДНК, кодирующая указанный β-амилоидный пептид, включает в себя нуклеотидную последовательность, приведенной в SEQ ID NO: 1.
6. Адено-ассоциированный вирусный вектор по п.1, где указанный β-амилоидный пептид включает в себя аминокислотную последовательность, приведенную в SEQ ID NO: 4.
7. Адено-ассоциированный вирусный вектор по п.1, где ДНК, кодирующая указанный β-амилоидный пептид, включает в себя нуклеотидную последовательность, приведенную в SEQ ID NO: 3.
8. Адено-ассоциированный вирусный вектор по п.1, где указанный сигнальный пептид представляет собой сигнальный пептид амилоидного белка-предшественника.
9. Адено-ассоциированный вирусный вектор по п.1, где указанный сигнальный пептид включает в себя аминокислотную последовательность, приведенную в SEQ ID NO: 6.
10. Адено-ассоциированный вирусный вектор по п.1, где ДНК, кодирующая указанный сигнальный пептид, включает в себя нуклеотидную последовательность, приведенной в SEQ ID NO: 5.
11. Фармацевтическая композиция для лечения болезни Альцгеймера, включающая в себя адено-ассоциированный вирусный вектор по любому из пп.1-10.
12. Фармацевтическая композиция по п.11 предназначена для перорального приема.
13. Способ лечения болезни Альцгеймера, включающий в себя введение субъекту адено-ассоциированного вирусного вектора по любому из пп.1-10 в терапевтически эффективных количествах.
14. Применение адено-ассоциированного вирусного вектора по любому из пп.1-10 для получения терапевтических средств для лечения болезни Альцгеймера.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2003-169714 | 2003-06-13 | ||
| JP2003169714 | 2003-06-13 | ||
| JP2003-371103 | 2003-10-30 | ||
| JP2003371103A JP4888876B2 (ja) | 2003-06-13 | 2003-10-30 | アルツハイマー病の治療のための組換えアデノ随伴ウィルスベクター |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2006101149A true RU2006101149A (ru) | 2006-06-27 |
| RU2335542C2 RU2335542C2 (ru) | 2008-10-10 |
Family
ID=33554414
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2006101149/13A RU2335542C2 (ru) | 2003-06-13 | 2004-06-11 | Аденоассоциированный вирусный вектор для лечения болезни альцгеймера, его применение для получения терапевтических средств, а также способ лечения болезни альцгеймера с помощью данного вектора |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US8318687B2 (ru) |
| EP (1) | EP1634956B1 (ru) |
| JP (1) | JP4888876B2 (ru) |
| KR (1) | KR20060029225A (ru) |
| AT (1) | ATE466093T1 (ru) |
| AU (1) | AU2004248014B2 (ru) |
| BR (1) | BRPI0411321A (ru) |
| CA (1) | CA2529179C (ru) |
| DE (1) | DE602004026867D1 (ru) |
| DK (1) | DK1634956T3 (ru) |
| ES (1) | ES2345151T3 (ru) |
| NZ (1) | NZ544554A (ru) |
| PT (1) | PT1634956E (ru) |
| RU (1) | RU2335542C2 (ru) |
| WO (1) | WO2004111250A1 (ru) |
Families Citing this family (54)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10303974A1 (de) | 2003-01-31 | 2004-08-05 | Abbott Gmbh & Co. Kg | Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung |
| KR100677051B1 (ko) | 2005-03-18 | 2007-02-01 | 주식회사 엘지화학 | 올레핀으로부터 불포화산을 제조하는 방법 |
| CN101228272A (zh) * | 2005-04-20 | 2008-07-23 | 生物载体株式会社 | 用于治疗阿尔茨海默病的具有较高安全性的经鼻腔内给药基因疫苗 |
| DE602006010064D1 (de) * | 2005-04-20 | 2009-12-10 | Dnavec Corp | Hochsichere intranasal verabreichbare genimpfstoffe zur behandlung von morbus alzheimer |
| WO2006126682A1 (ja) * | 2005-05-27 | 2006-11-30 | Juridical Foundation The Chemo-Sero-Therapeutic Research Institute | アルツハイマー病の予防・治療用ワクチン |
| JP5220597B2 (ja) | 2005-06-23 | 2013-06-26 | キージーン ナムローゼ フェンノートシャップ | １つ又は複数の多型性を同定する方法およびその使用方法 |
| US10316364B2 (en) | 2005-09-29 | 2019-06-11 | Keygene N.V. | Method for identifying the source of an amplicon |
| ATE453728T1 (de) | 2005-09-29 | 2010-01-15 | Keygene Nv | Screening mutagenisierter populationen mit hohem durchsatz |
| AU2006319358B2 (en) | 2005-11-30 | 2012-01-19 | AbbVie Deutschland GmbH & Co. KG | Anti-Abeta globulomer antibodies, antigen-binding moieties thereof, corresponding hybridomas, nucleic acids, vectors, host cells, methods of producing said antibodies, compositions comprising said antibodies, uses of said antibodies and methods of using said antibodies |
| KR20140087058A (ko) | 2005-11-30 | 2014-07-08 | 애브비 인코포레이티드 | 아밀로이드 베타 단백질에 대한 모노클로날 항체 및 이의 용도 |
| US8481257B2 (en) | 2005-12-22 | 2013-07-09 | Keygene N.V. | Method for high-throughput AFLP-based polymorphism detection |
| EP2963127B1 (en) | 2006-04-04 | 2017-08-16 | Keygene N.V. | High throughput detection of molecular markers based on restriction fragments |
| US8455626B2 (en) | 2006-11-30 | 2013-06-04 | Abbott Laboratories | Aβ conformer selective anti-aβ globulomer monoclonal antibodies |
| US8895004B2 (en) | 2007-02-27 | 2014-11-25 | AbbVie Deutschland GmbH & Co. KG | Method for the treatment of amyloidoses |
| US8673846B2 (en) | 2009-11-02 | 2014-03-18 | Toagosei Co. Ltd. | Cell proliferation-promoting peptide and use thereof |
| JP5697044B2 (ja) * | 2010-01-08 | 2015-04-08 | 国立大学法人京都大学 | タウオパチー治療用ワクチン |
| CA2796339C (en) | 2010-04-15 | 2020-03-31 | Abbott Laboratories | Amyloid-beta binding proteins |
| JP5854283B2 (ja) | 2010-06-04 | 2016-02-09 | 東亞合成株式会社 | 細胞増殖促進ペプチド及びその利用 |
| US9238796B2 (en) | 2010-06-04 | 2016-01-19 | Toagosei Co. Ltd. | Cell growth-promoting peptide and use thereof |
| JP6147665B2 (ja) | 2010-08-14 | 2017-06-14 | アッヴィ・インコーポレイテッド | アミロイドベータ結合タンパク質 |
| PE20150163A1 (es) | 2012-04-18 | 2015-02-23 | Philadelphia Children Hospital | Composicion y metodos para una transferencia de genes altamente eficiente usando variantes capside aav |
| WO2013180011A1 (ja) | 2012-05-28 | 2013-12-05 | 東亞合成株式会社 | 抗菌ペプチド及びその利用 |
| WO2014061749A1 (ja) | 2012-10-18 | 2014-04-24 | 東亞合成株式会社 | ２型ｔｎｆ受容体の発現を抑制する合成ペプチド及びその利用 |
| WO2015017280A1 (en) | 2013-07-28 | 2015-02-05 | Qantu Therapeutics, Inc. | Vaccine formulations that induce a th2 immune response |
| EP3151866B1 (en) | 2014-06-09 | 2023-03-08 | Voyager Therapeutics, Inc. | Chimeric capsids |
| SG11201703148TA (en) | 2014-11-05 | 2017-05-30 | Voyager Therapeutics Inc | Aadc polynucleotides for the treatment of parkinson's disease |
| CN114717264A (zh) | 2014-11-14 | 2022-07-08 | 沃雅戈治疗公司 | 治疗肌萎缩性侧索硬化(als)的组合物和方法 |
| CN107207556B (zh) | 2014-11-14 | 2020-12-08 | 沃雅戈治疗公司 | 调节性多核苷酸 |
| WO2016094783A1 (en) | 2014-12-12 | 2016-06-16 | Voyager Therapeutics, Inc. | Compositions and methods for the production of scaav |
| EP3384035A4 (en) | 2015-12-02 | 2019-08-07 | Voyager Therapeutics, Inc. | ASSAYS FOR THE DETECTION OF AAV-NEUTRALIZING ANTIBODIES |
| EP3448987A4 (en) | 2016-04-29 | 2020-05-27 | Voyager Therapeutics, Inc. | COMPOSITIONS FOR TREATING A DISEASE |
| EP3448874A4 (en) | 2016-04-29 | 2020-04-22 | Voyager Therapeutics, Inc. | COMPOSITIONS FOR TREATING A DISEASE |
| KR102652994B1 (ko) | 2016-05-18 | 2024-04-01 | 보이저 테라퓨틱스, 인크. | 조절성 폴리뉴클레오티드 |
| IL297576B2 (en) | 2016-05-18 | 2024-02-01 | Voyager Therapeutics Inc | Compositions and methods of treating huntington's disease |
| EP3506817A4 (en) | 2016-08-30 | 2020-07-22 | The Regents of The University of California | Methods for biomedical targeting and delivery and devices and systems for practicing the same |
| AU2018206304A1 (en) | 2017-01-06 | 2019-07-04 | Stabilitech Biopharma Ltd | Virus |
| EP3618839A4 (en) | 2017-05-05 | 2021-06-09 | Voyager Therapeutics, Inc. | Compositions and methods of treating amyotrophic lateral sclerosis (als) |
| CN111108198A (zh) | 2017-05-05 | 2020-05-05 | 沃雅戈治疗公司 | 治疗亨廷顿病的组合物和方法 |
| JOP20190269A1 (ar) | 2017-06-15 | 2019-11-20 | Voyager Therapeutics Inc | بولي نوكليوتيدات aadc لعلاج مرض باركنسون |
| AU2018302016A1 (en) | 2017-07-17 | 2020-02-06 | The Regents Of The University Of California | Trajectory array guide system |
| WO2019023247A1 (en) | 2017-07-25 | 2019-01-31 | Immutics, Inc. | TREATMENT OF CANCER BY BLOCKING THE INTERACTION OF TIM-3 AND ITS LIGAND |
| EP3662060A2 (en) | 2017-08-03 | 2020-06-10 | Voyager Therapeutics, Inc. | Compositions and methods for delivery of aav |
| WO2019067840A1 (en) | 2017-09-29 | 2019-04-04 | Voyager Therapeutics, Inc. | RESTRICTING CENTRAL AND PERIPHERAL NEUROLOGICAL PHENOTYPE FROM FRIEDREICH ATAXIA BY INTRAVENOUS ADMINISTRATION |
| CA3077426A1 (en) | 2017-10-16 | 2019-04-25 | Voyager Therapeutics, Inc. | Treatment of amyotrophic lateral sclerosis (als) |
| EP4454654A3 (en) | 2017-10-16 | 2025-02-19 | Voyager Therapeutics, Inc. | Treatment of amyotrophic lateral sclerosis (als) |
| CA3099306A1 (en) | 2018-05-15 | 2019-11-21 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of parkinson's disease |
| WO2020030954A1 (en) | 2018-08-09 | 2020-02-13 | Integrative Medicine Clinic, Sia | Theranostics-like protein sanps conjugated to integrin and pmsa targeting peptides and therapy of prostate cancer |
| US12281321B2 (en) | 2018-09-28 | 2025-04-22 | Voyager Therapeutics, Inc. | Frataxin expression constructs having engineered promoters and methods of use thereof |
| JP2022523333A (ja) | 2019-01-30 | 2022-04-22 | トゥルーバインディング，インコーポレイテッド | 抗ｇａｌ３抗体およびその使用 |
| EP4157338A4 (en) | 2020-05-26 | 2024-11-13 | TrueBinding, Inc. | METHOD FOR TREATING INFLAMMATORY DISEASES BY GALECTIN-3 BLOCKING |
| US20230227802A1 (en) | 2020-07-27 | 2023-07-20 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of neurological disorders related to glucosylceramidase beta deficiency |
| WO2022026410A2 (en) | 2020-07-27 | 2022-02-03 | Voyager Therapeutics, Inc | Compositions and methods for the treatment of niemann-pick type c1 disease |
| EP4433490A2 (en) | 2021-11-17 | 2024-09-25 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of neurological disorders related to glucosylceramidase beta deficiency |
| WO2024163012A1 (en) | 2023-02-02 | 2024-08-08 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of neurological disorders related to glucosylceramidase beta deficiency |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5854204A (en) * | 1995-03-14 | 1998-12-29 | Praecis Pharmaceuticals, Inc. | Aβ peptides that modulate β-amyloid aggregation |
| US5858351A (en) | 1996-01-18 | 1999-01-12 | Avigen, Inc. | Methods for delivering DNA to muscle cells using recombinant adeno-associated virus vectors |
| US7964192B1 (en) * | 1997-12-02 | 2011-06-21 | Janssen Alzheimer Immunotherapy | Prevention and treatment of amyloidgenic disease |
| TWI239847B (en) * | 1997-12-02 | 2005-09-21 | Elan Pharm Inc | N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease |
| AU2486900A (en) * | 1998-12-29 | 2000-07-31 | University Of Georgia Research Foundation, Inc., The | Rubredoxin fusion proteins, protein expression system and methods |
| EP1204674A4 (en) * | 1999-07-27 | 2005-06-01 | Abgenix Inc | METHODS AND COMPOUNDS FOR PREVENTING POLYPEPTIDE COLLECTIONS ASSOCIATED WITH NEUROLOGICAL DISORDERS |
| US20030165481A1 (en) * | 2000-02-24 | 2003-09-04 | Hersh Louis B. | Amyloid peptide inactivating enzyme to treat Alzheimer's disease |
| EP1538163A3 (en) * | 2000-11-01 | 2005-06-15 | Insight Biotechnology Limited | Phosphorylated Amyloid-Beta 1-43 Protein and its use in the treatment of Alzheimer's disease |
| US6906169B2 (en) * | 2001-05-25 | 2005-06-14 | United Biomedical, Inc. | Immunogenic peptide composition comprising measles virus Fprotein Thelper cell epitope (MUFThl-16) and N-terminus of β-amyloid peptide |
| CN100450551C (zh) * | 2002-11-29 | 2009-01-14 | 中国医学科学院基础医学研究所 | 用于治疗和预防阿尔茨海默病的重组腺相关病毒基因疫苗及其用途 |
-
2003
- 2003-10-30 JP JP2003371103A patent/JP4888876B2/ja not_active Expired - Lifetime
-
2004
- 2004-06-11 AT AT04745818T patent/ATE466093T1/de not_active IP Right Cessation
- 2004-06-11 AU AU2004248014A patent/AU2004248014B2/en not_active Ceased
- 2004-06-11 KR KR1020057023896A patent/KR20060029225A/ko not_active Ceased
- 2004-06-11 EP EP04745818A patent/EP1634956B1/en not_active Expired - Lifetime
- 2004-06-11 CA CA2529179A patent/CA2529179C/en not_active Expired - Fee Related
- 2004-06-11 ES ES04745818T patent/ES2345151T3/es not_active Expired - Lifetime
- 2004-06-11 US US10/560,280 patent/US8318687B2/en not_active Expired - Fee Related
- 2004-06-11 DE DE602004026867T patent/DE602004026867D1/de not_active Expired - Lifetime
- 2004-06-11 WO PCT/JP2004/008224 patent/WO2004111250A1/ja not_active Ceased
- 2004-06-11 DK DK04745818.7T patent/DK1634956T3/da active
- 2004-06-11 NZ NZ544554A patent/NZ544554A/en unknown
- 2004-06-11 PT PT04745818T patent/PT1634956E/pt unknown
- 2004-06-11 BR BRPI0411321-7A patent/BRPI0411321A/pt not_active IP Right Cessation
- 2004-06-11 RU RU2006101149/13A patent/RU2335542C2/ru not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| EP1634956A4 (en) | 2007-01-24 |
| JP2005021149A (ja) | 2005-01-27 |
| RU2335542C2 (ru) | 2008-10-10 |
| BRPI0411321A (pt) | 2006-07-18 |
| CA2529179A1 (en) | 2004-12-23 |
| EP1634956A1 (en) | 2006-03-15 |
| NZ544554A (en) | 2010-06-25 |
| DE602004026867D1 (de) | 2010-06-10 |
| AU2004248014A1 (en) | 2004-12-23 |
| JP4888876B2 (ja) | 2012-02-29 |
| US8318687B2 (en) | 2012-11-27 |
| ATE466093T1 (de) | 2010-05-15 |
| KR20060029225A (ko) | 2006-04-05 |
| WO2004111250A1 (ja) | 2004-12-23 |
| CA2529179C (en) | 2012-08-21 |
| ES2345151T3 (es) | 2010-09-16 |
| PT1634956E (pt) | 2010-06-23 |
| DK1634956T3 (da) | 2010-08-16 |
| US20090004144A1 (en) | 2009-01-01 |
| EP1634956B1 (en) | 2010-04-28 |
| AU2004248014B2 (en) | 2008-12-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2006101149A (ru) | Рекомбинантный адено-ассоциированный вирусный вектор для лечения болезни альцгеймера | |
| RU2468080C2 (ru) | Новый класс терапевтических белковых молекул | |
| ES2341534T3 (es) | Peptidos como inhibidores de la serina proteasa ns3 del virus de la hepatitis c. | |
| ES2327819T3 (es) | Imidazolidinonas como inhibidores de la serina proteasa ns3 del virus de la hepatitis c. | |
| ES2870914T3 (es) | Péptidos intestinales vasoactivos modificados | |
| RU2002113920A (ru) | Антигенные пептиды neisseria | |
| RU2001134170A (ru) | Антигенные пептиды NEISSERIA | |
| RU2000124084A (ru) | Химерное антитело, которое связывается с CD40 человека (варианты), молекула нуклеиновой кислоты (варианты), вектор экспрессии (варианты), гуманизированное антитело (варианты), фармацевтическая композиция для лечения заболевания, опосредованного Т-клетками (варианты), способ лечения больного от заболевания, опосредованного Т-клетками (варианты) | |
| JP2003500040A5 (ru) | ||
| JP2005530484A5 (ru) | ||
| RU2012107671A (ru) | Композиция для лечения инфекции вирусом гепатита в | |
| RU2002103604A (ru) | Антигенные менингококковые пептиды | |
| EA200501007A1 (ru) | Композиции и способы для усовершенствованной доставки пептидов, связывающихся с y2-рецепторами, которую осуществляют через слизистые оболочки, и способы лечения и предотвращения ожирения | |
| RU2012102339A (ru) | Полипептиды из neisseria meningitidis | |
| HRP20041108B1 (hr) | Peptidi povezani sa tumorom koji se vežu na mhc molekule | |
| JP2005538932A5 (ru) | ||
| DE68929466D1 (de) | Menschlicher rezeptor c3b/c4b (cr1) | |
| DK1349944T3 (da) | Latensassocieret peptid af TGF-beta til at bibringe farmaceutisk aktive proteiner latens | |
| RU2005113692A (ru) | Вакцина против hcv | |
| JPH09289896A5 (ru) | ||
| Bolon et al. | Animal toxins | |
| HUP0100267A2 (hu) | Helicobacter pylori eredetű nukleinsav- és aminosav-szekvenciák és a megfelelő nukleinsavakat vagy peptideket tartalmazó vakcina-készítmények | |
| DE50010519D1 (de) | Pharmazeutische Zusammensetzungen zur Therapie der Herzinsuffizienz | |
| RU2214273C2 (ru) | ДНК-ПОСЛЕДОВАТЕЛЬНОСТИ, КОДИРУЮЩИЕ ЧЕЛОВЕЧЕСКИЕ ПРОТЕИНЫ Tx И Ty, РОДСТВЕННЫЕ КОНВЕРГИРУЮЩЕМУ ИНТЕРЛЕЙКИН-1-β ФЕРМЕНТУ | |
| EP0834568A3 (en) | Novel saliva binding protein |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PC41 | Official registration of the transfer of exclusive right |
Effective date: 20110726 |
|
| PC41 | Official registration of the transfer of exclusive right |
Effective date: 20111121 |
|
| TK4A | Correction to the publication in the bulletin (patent) |
Free format text: AMENDMENT TO CHAPTER -PC4A- IN JOURNAL: 36-2011 |
|
| MM4A | The patent is invalid due to non-payment of fees |
Effective date: 20140612 |